New hope for 10x’ preliminary injunction after EPO Opposition Division ruling | Patent at issue concerns single-cell spatial ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

Single-cell transcriptomics has revolutionized the study of cellular diversity and function by enabling gene expression ...

Let's explore the potentials of these low-cap meme coins that could propel them to 10x investors' portfolios. Shiba Inu (SHIB): The Meme Coin That's Turning Investors Into Millionaires Shiba Inu ...

Currently priced at $0.09, INTL could be poised for 10x gains which could make it an attractive option for traders seeking innovation and growth. Could INTL be the next big AI-powered crypto project ...

Popcorn is one of my all-time favorite snacks, especially now that I have to eat gluten-free. It's a quick way to fill me up without having to worry about what's in it. Whether it's buttery movie ...

Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

1. AI-Driven Genomics For Precision Medicine AI has revolutionized genomic medicine, paving the way for rapid advancements in precision medicine, a key focus for the future. Cancer is recognized ...